J.P. Morgan has officially jumped into early stage biotech investing

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Good morning. We’ve made it to the end of the week! Let’s keep it short and get straight to the news of the day.

The need-to-know this morning

• Cabaletta Bio presented early data on an experimental CD-19 targeting CAR-T therapy for autoimmune disease at a European rheumatology meeting.

Industry cheers Supreme Court decision on abortion pill

Biopharma leaders applauded the Supreme Court’s ruling yesterday that anti-abortion doctors did not have standing to challenge the FDA’s regulation of the abortion pill mifepristone.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts.

Already have an account? Log in

Individual plans

Group plans

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $399/year

$30 for 3 months Get Started

Then $399/year

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

To read the rest of this story subscribe to STAT+.

Subscribe

Log In